- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04348513
Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)
Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It seems that thyroid hormone is critical in the response to body injury and is now considered as potential pharmaceutical intervention to limit acute tissue injury. TH (via its regulation of stress induced p38 MAPK activation) exerts antiapoptotic action and protects tissue from injury, with additional favorable effects on immune system and on viral load in infected tissue. This may be a novel and more effective treatment for critically ill viral infected patients.
ThyRepair is the first study which is underway and investigates the safety and efficacy of high dose T3 treatment in patients with acute myocardial infarction undergoing primary angioplasty. The preliminary reports show that this treatment is safe and the efficacy on tissue repair is promising. This therapeutic modality could also be tested in the acute setting of sepsis in which thyroid hormone is involved in the pathophysiology of multi-organ dysfunction. The safety and efficacy of T3 on heamodynamics in sepsis has been previously demonstrated in a small trial.
The present study is phase II, parallel, prospective, randomized, double-blind, placebo controlled trial which aims to investigate the potential effect of T3 intravenous use in the recovery of critically ill patients admitted in ICU due to COVID19 infection.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Haidari/Athens, Greece, 12462
- Attikon University General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with pulmonary infection due to COVID-19, admitted in ICU and require mechanical ventilation or ECMO
- Male and female with Age>18 years old
- Signed informed consent from patient or relatives
Exclusion Criteria:
- Pregnant or breast-feeding women
- Severe systemic disease (cancer, auto-immune etc) before infection accompanied by reduced life expectancy <6 months
- Participation in another trial of an investigational drug or device
- Corticosteroid Use before initiation of treatment
- Sympathomimetic Use before initiation of treatment (epinephrine, norepinephrine, dobutamine, dopamine, phenylephrine)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T3 solution for injection
T3 Solution for injection 10 μg/ml, each vial contains 150μg of liothyronine in a total volume of 15ml.
The dose administered will be 0.8g/kg i.v.
bolus starting within 60min after respiratory support and will be followed by an infusion of 0.113g.
kg-1.h-1
i.v. for 48 hours (therapeutic dose).
After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g.
kg-1.h-1
i.v.).
Drug administration will stop after successful weaning or end of followup (maximum 30 days).
|
For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation.
Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours.
From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.
|
Placebo Comparator: Placebo
Composition identical apart from the active substance.
Same dosage.
|
Same as with T3 solution for injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of weaning from cardiorespiratory support
Time Frame: 30 days
|
The primary objective of the study is to determine whether the administration of intravenous triiodothyronine in ICU patients diagnosed with pulmonary infection due to COVID-19 facilitates weaning from cardiorespiratory support compared to placebo.
Successful weaning is defined as no requirement for ventilatory support after extubation (mechanical support) or support from ECMO for 48 hours.
The primary objective will be measured as percentage of patients successfully weaned after 30 days of follow-up.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of hemodynamic status
Time Frame: 30 days
|
Hemodynamic status will be assessed by continuous blood pressure measurements (systolic BP in mmHg)
|
30 days
|
Assessment of hemodynamic status
Time Frame: 30 days
|
Hemodynamic status will be assessed by continuous blood pressure measurements (diastolic BP in mmHg)
|
30 days
|
Assessment of hemodynamic status
Time Frame: 30 days
|
Hemodynamic status will be assessed by continuous blood pressure measurements (mean BP in mmHg)
|
30 days
|
Assessment of hemodynamic status
Time Frame: 30 days
|
Hemodynamic status will be assessed by the number of participants with use of inotropic and vasoactive drugs
|
30 days
|
Assessment of pulmonary function
Time Frame: 30 days
|
Pulmonary function will be assessed by arterial measurement of blood gases (arterial partial pressure of oxygen in mmHg)
|
30 days
|
Assessment of pulmonary function
Time Frame: 30 days
|
Pulmonary function will be assessed by arterial measurement of blood gases (arterial partial pressure of carbon dioxide in mmHg)
|
30 days
|
Assessment of pulmonary function
Time Frame: 30 days
|
Pulmonary function will be assessed by arterial measurement of lactate levels (in mmol/L)
|
30 days
|
Assessment of hepatic function
Time Frame: 30 days
|
Hepatic function will be assessed by laboratory measurements in blood.
Changes in aspartate aminotransferase (AST in IU/L) will be measured.
|
30 days
|
Assessment of hepatic function
Time Frame: 30 days
|
Hepatic function will be assessed by laboratory measurements in blood.
Changes in alanine aminotransferase (ALT in IU/L) will be measured.
|
30 days
|
Assessment of hepatic function
Time Frame: 30 days
|
Hepatic function will be assessed by laboratory measurements in blood.
Changes in gamma-glutamyl transpeptidase (γ-GT in IU/L) will be measured.
|
30 days
|
Assessment of hepatic function
Time Frame: 30 days
|
Hepatic function will be assessed by laboratory measurements in blood.
Changes in bilirubin in mg/dL will be measured.
|
30 days
|
Assessment of hepatic function
Time Frame: 30 days
|
Hepatic function will be assessed by laboratory measurements in blood.
Changes in fibrinogen in mg/dL will be measured.
|
30 days
|
Assessment of hepatic function
Time Frame: 30 days
|
Hepatic function will be assessed by laboratory measurements in blood.
Changes in d-dimers in ng/ml will be measured.
|
30 days
|
Assessment of renal function
Time Frame: 30 days
|
Urine volume during 24 hours (in ml) will be recorded.
|
30 days
|
Assessment of renal function
Time Frame: 30 days
|
Changes in urea (in mg/dL) will be recorded.
|
30 days
|
Assessment of renal function
Time Frame: 30 days
|
Changes in uric acid (in mg/dL) will be recorded.
|
30 days
|
Assessment of renal function
Time Frame: 30 days
|
Changes in creatinine (in mg/dL) will be recorded.
|
30 days
|
Assessment of cardiac function
Time Frame: 30 days
|
Echocardiographic assessment of cardiac left ventricular ejection fraction (LVEF, %)
|
30 days
|
Assessment of cardiac injury
Time Frame: 30 days
|
Measurements of cardiac troponin I (in μg/L) will be used to assess myocardial injury
|
30 days
|
Assessment of the course of COVID-19 infection
Time Frame: 30 days
|
COVID-19 infection will be assessed by inflammatory indices in blood (white blood cells in number per μL)
|
30 days
|
Assessment of the course of COVID-19 infection
Time Frame: 30 days
|
COVID-19 infection will be assessed by inflammatory indices in blood (CRP in mg/L)
|
30 days
|
Assessment of the course of COVID-19 infection
Time Frame: 30 days
|
COVID-19 infection will be assessed by inflammatory indices in blood (erythrocyte sedimentation rate in mm/hr)
|
30 days
|
Assessment of the course of COVID-19 infection
Time Frame: 30 days
|
COVID-19 infection will be assessed by temperature monitoring (in degrees Celsius)
|
30 days
|
Assessment of the course of COVID-19 infection
Time Frame: 30 days
|
COVID-19 infection will be assessed by time needed (in days) for the patient to become negative in COVID-19
|
30 days
|
Assessment of clinical outcome and safety
Time Frame: 30 days
|
Number of participants with major (death, cardiac Arrest, electromechanical dissociation, pulmonary embolism, new myocardial infarction, stroke, pulmonary edema, cardiogenic shock and hypotension, septic shock, pulmonary embolism, serious bleeding) events be recorded during the follow up period
|
30 days
|
Assessment of clinical outcome and safety
Time Frame: 30 days
|
Number of participants with minor (myocarditis, Venous Thromboembolism, left Ventricular mural thrombus, renal failure, hepatic failure, stress ulcers, minor bleeding, paroxysmal supraventricular tachycardia and atrial fibrillation, rhythm disturbances) events will be recorded during the follow up period
|
30 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Georgia Kostopanagiotou, MD, Attikon University General Hospital
Publications and helpful links
General Publications
- Pantos C, Apostolaki V, Kokkinos L, Trikas A, Mourouzis I. Acute triiodothyronine treatment and red blood cell sedimentation rate (ESR) in critically ill COVID-19 patients: A novel association? Clin Hemorheol Microcirc. 2021;79(3):485-488. doi: 10.3233/CH-211215.
- Pantos C, Kostopanagiotou G, Armaganidis A, Trikas A, Tseti I, Mourouzis I. Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 26;21(1):573. doi: 10.1186/s13063-020-04474-0.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- T3inj-02/ThySupport
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on T3 solution for injection
-
Boehringer IngelheimRecruitingNetherton SyndromeBelgium, United Kingdom, Australia, Germany, China, Malaysia, Japan, France, United States, Israel, Bulgaria, Italy, Switzerland, Austria, Netherlands, Portugal
-
10xBio, LLCActive, not recruitingSubmental FatUnited States
-
GlaxoSmithKlineCompleted
-
10xBio, LLCTherapeutics, Inc.Active, not recruitingSubcutaneous Fat DisorderUnited States
-
Ferring PharmaceuticalsCompleted
-
Mayo ClinicRecruitingLower Urinary Tract Obstructive Syndrome | Renal Failure Congenital | Congenital Renal Anomaly Nos | Renal Agenesis and DysgenesisUnited States
-
Fundación Pública Andaluza para la gestión de la...TerminatedCrohn Disease | Ulcerative ColitisSpain
-
AstraZenecaQuotient SciencesCompletedChronic Kidney Disease | Type 2 Diabetes Mellitus (T2DM) | Non-alcoholic SteatohepatitisUnited Kingdom
-
Association pour le Développement et l'Organisation...CompletedAcute Circulatory Failure
-
Helsinn Therapeutics (U.S.), IncCompletedGastrointestinal DysmotilityUnited States